Decision Resources, Inc., one of the world's leading research and advisory firms focusing on pharmaceutical and health care issues, forecasts that despite looming patent expirations for several key therapies, steady growth is forecasted for the ST-segment elevation myocardial infarction (STEMI) drug market in the new Pharmacor report entitled Acute Myocardial Infarction.
"Besides the patent expiries, the drug market for acute myocardial infarction (AMI) is also facing a trend toward increased use of mechanical reperfusion for STEMI," said Mark Thornton, Ph.D., analyst at Decision Resources. "Growth for this market will result largely from expanded use of polypharmacy and facilitated percutaneous coronary intervention (PCI), which combines pharmacological thrombolysis, antithrombotic therapy, and mechanical reperfusion."
Disease Background-Acute Myocardial Infarction
Although progress has been made in reducing the mortality associated with AMI, the condition is still one of the most widespread and serious health problems in Western society. Types of AMI are classified by the presence or absence of changes to the "ST-segment" of the cardiac cycle: ST-segment elevation myocardial infarctions (STEMIs) and non -ST-segment elevation myocardial infarctions (NSTEMIs). In 2001, there were more than 719,000 diagnosed STEMI incident events in the world's seven major pharmaceutical markets (United States, France, Germany, Italy, Spain, United Kingdom, and Japan). In 2011, the number of diagnosed incident events could grow to more than 841,000, expanding the market for more effective and convenient STEMI drug therapies.
About Pharmacor from Decision Resources
Pharmacor is a unique family of studies based on primary and secondary research conducted by Decision Resources' on-staff experts. Each comprehensive study assesses a host of market-impacting factors and analyzes the commercial outlook for drugs in research and development. Cardium, Cognos, Immune and Inflammatory Disorders, Infectious Disease, Metabolic Disorders, Psychiatric Disorders, and Onkos concentrate on specific therapeutic areas. Mosaic covers high-interest disease states. Acute Myocardial Infarction is a Cardium study.
About Decision Resources
Decision Resources, Inc., is a world leader in research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets. The company provides strategic information services, and assesses international pharmaceutical and health care industry trends. Visit Decision Resources at www.decisionresources.com.
All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.
For more information, contact: Elizabeth Marshall Decision Resources, Inc. 781-296-2563 firstname.lastname@example.org
SOURCE: Decision Resources, Inc.
CONTACT: Elizabeth Marshall of Decision Resources, Inc., +1-781-296-2563,
Web site: http://www.dresources.com/